Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it has signed an exclusive contract manufacturing agreement with Bio V Pharma Inc. (“BioV”). Per the agreement, BioV, a Quebec-based full-service manufacturer of pharmaceutical and nutraceutical products, will manufacture, label, package and supply Pivot’s entire bio-cannabis suite of products. In addition, Pivot has engaged Cannabis Compliance Inc. to apply to Health Canada for a Dealer’s License under the Controlled Drugs and Substances Act and the Narcotic Control Regulations. A Dealer’s License would enable the company to perform research and development, process natural health products, store cannabis derivatives, as well as import and export cannabis oils, concentrates and approved derivatives at the BioV facility. “BioV has a track record of supplying retail pharmacy chains, including Shoppers Drug Mart and London Drugs, with products meeting the highest quality standards. We continue to execute on our business plan to monetize our platform technologies by commercializing our suite of premium, science-based cannabis products in key markets,” Pivot Pharmaceuticals CEO Dr. Patrick Frankham stated in the news release.
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly owned medical cannabis products division, Pivot Green StreamHealth Solutions Inc. (“PGS”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol, and tetrahydrocannabinol-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information, visit the company’s website at www.PivotPharma.com.